A Phase 1, Single Dose Pk And Safety Study With Ni-03 Followed By A Phase 2, Randomized, Double-Blind, Parallel-Group Dose-Ranging Study To Evaluate The Safety And Efficacy Of Ni-03 Compared To Placebo In Subjects With Chronic Pancreatitis
Principal Investigator (?)
The purpose of this study is to determine the safety and efficacy of NI-03.
Stason Pharmaceuticals Inc.
Available at the following location(s)
- Decision-Making Help
- Medical Records & Release Forms
- Health Encyclopedia
- Clinical Trials
- Lifestyle Changes
- Emmi® Patient Education
- Frequently Asked Questions on Scabies